<DOC>
	<DOCNO>NCT01361009</DOCNO>
	<brief_summary>This open-label , multicenter , non-interventional , prospective observational study . collect safety information pramipexole 12w treatment . Parkinson disease patient different severity already use pramipexole could observe study . In whole observation period , treatment decision determine physician patient completely . The safety endpoint AE ( Adverse Event ) , SAE ( Serious Adverse Event ) , patient withdraw , laboratory test .</brief_summary>
	<brief_title>PMS Safety Profile Pramipexole Chinese Parkinson Disease Patients</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosed idiopathic PD ( Parkinson ' disease ) accord UK brain bank criterion 2 . Age : 30 75 year old 3 . Stage IIV revise HoehnYahr standard 4 . With current use pramipexole 5 . Informed consent sign every subject Exclusion criterion : 1 . Diagnosis ParkinsonÂ¿s syndrome 2 . Current use psychotolytic medication 3 . Allergic pramipexole ingredient pramipexole 4 . Female patient pregnancy lactation 5 . Patients participate clinical study sign relevant informed consent receive investigational drug within 30 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>